Lexaria Bioscience (LEXX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Lexaria Bioscience’s DehydraTECH technology has shown promising results in a 12-week diabetes animal study by outperforming the Rybelsus® control group in body weight and blood sugar control. The DehydraTECH-liraglutide and DehydraTECH-CBD formulations were particularly effective, highlighting the potential of this innovative drug delivery platform.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
